Future research aims to enhance TALEN's efficiency and specificity, potentially combining it with CRISPR or base editing technologies for advanced genetic engineering applications. Despite its ...

Dana Carroll must be considered one of the deans of genome editing. He was instrumental in the development of zinc finger nucleases (ZFNs), the genome editing tool that predates CRISPR-Cas by a full ...

Allogene Therapeutics is a clinical-stage biotech developing allogeneic CAR T therapies for cancer and autoimmune diseases, with a focus on Cema-cel for LBCL. ALLO's advanced gene-editing platforms, ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

Zinc finger nucleases (ZFNs) have great potential for translational research and clinical use. Scientists succeeded in the efficient construction of functional ZFNs and the improvement of their genome ...

Based on Offerings, the market is divided into products and services segments. The products segment accounted for the largest share of the gene editing market in 2023. The large share of products is ...